“4) Failure of RRR for MACE but success with both eGFR and MOCA.

5) Faiure of RRR for MACE but success with one of eGFR or MOCA”

I don’t see either of these scenarios resulting in a share price of 20 or 30 cents.

A small oral molecule that has the ability to improve renal function/delay declining renal function and/or improve cognition/delay dementia has huge value to Big Pharma.

A treatment with cognitive effects would not need MACE data in any shape or form to be eventually approved by the FDA.

Big Pharma will be glad to take over and I’m confident Dart and Hepalink would provide the financial stability necessary to see such a deal come to fruition.

At Voisey’s Bay, Diamond Fields was looking for diamonds and found an incredibly rich base metal discovery. It sold for Billions despite not finding diamonds.

bfw